These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23768813)

  • 1. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
    Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
    Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
    J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
    Deutsch SI; Schwartz BL; Schooler NR; Rosse RB; Mastropaolo J; Gaskins B
    Clin Neuropharmacol; 2008; 31(1):34-9. PubMed ID: 18303489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
    J Psychopharmacol; 2023 Apr; 37(4):381-395. PubMed ID: 36927273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
    Int J Psychophysiol; 2019 Nov; 145():70-82. PubMed ID: 30790597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
    Psychopharmacology (Berl); 2020 Dec; 237(12):3665-3687. PubMed ID: 32851421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
    Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
    Kelly DL; McMahon RP; Weiner E; Boggs DL; Dickinson D; Conley RR; Buchanan RW
    Schizophr Res; 2008 Aug; 103(1-3):161-8. PubMed ID: 18550339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of galantamine on psychopathology in chronic stable schizophrenia.
    Conley RR; Boggs DL; Kelly DL; McMahon RP; Dickinson D; Feldman S; Ball MP; Buchanan RW
    Clin Neuropharmacol; 2009; 32(2):69-74. PubMed ID: 18978489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galantamine for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW; Conley RR; Dickinson D; Ball MP; Feldman S; Gold JM; McMahon RP
    Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
    Beinat C; Banister SD; Herrera M; Law V; Kassiou M
    CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
    Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288.
    Gee KW; Olincy A; Kanner R; Johnson L; Hogenkamp D; Harris J; Tran M; Edmonds SA; Sauer W; Yoshimura R; Johnstone T; Freedman R
    J Psychopharmacol; 2017 Apr; 31(4):434-441. PubMed ID: 28196430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
    Umbricht D; Keefe RS; Murray S; Lowe DA; Porter R; Garibaldi G; Santarelli L
    Neuropsychopharmacology; 2014 Jun; 39(7):1568-77. PubMed ID: 24549101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α7 nicotinic receptor agonist and positive allosteric modulators differently improved schizophrenia-like cognitive deficits in male rats.
    Unal G; Sirvanci S; Aricioglu F
    Behav Brain Res; 2021 Jan; 397():112946. PubMed ID: 33011186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.
    Nikiforuk A; Kos T; Hołuj M; Potasiewicz A; Popik P
    Neuropharmacology; 2016 Feb; 101():389-400. PubMed ID: 26232639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
    Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
    Preskorn SH; Gawryl M; Dgetluck N; Palfreyman M; Bauer LO; Hilt DC
    J Psychiatr Pract; 2014 Jan; 20(1):12-24. PubMed ID: 24419307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.